Lipeo-sCT: A novel reversible lipidized salmon calcitonin derivative, its biophysical properties and hypocalcemic activity

European Journal of Pharmaceutical Sciences

Volumn 37, Issue 2, 2009, Pages 151-159

  Cheng, Weiqiang ^a   Lim, Lee Yong ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Activity; Aggregation; Characterization; Cytotoxicity; Disulfide; Lipidization; Non ionic surfactant; Pharmacokinetics; Salmon calcitonin; Synthesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOPHILE; CALCIUM; LIPEO SALMON CALCITONIN; SALCATONIN; TRIETHYLENE GLYCOL; TRIETHYLENE GLYCOL MONOHEXYLDECYL ETHER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM BLOOD LEVEL; CELL STRAIN CACO 2; CONTROLLED STUDY; DISULFIDE BOND; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; LIGHT SCATTERING; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BIOPHYSICS; CACO-2 CELLS; CALCITONIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; HYPOCALCEMIA; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, TRANSMISSION; PARTICLE SIZE; RATS; RATS, WISTAR;

EID: 62749088538     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.02.004     Document Type: Article

References (48)

1. Azria M. The Calcitonins: Physiology and Pharmacology (1989), Karger, Basel, New York
2. Carlsson J., Drevin H., and Axen R. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 173 (1978) 723-737
3. Carpenter J.F., Randolph T.W., Jiskoot W., Crommelin D.J., Middaugh C.R., Winter G., Fan Y.X., Kirshner S., Verthelyi D., Kozlowski S., Clouse K.A., Swann P.G., Rosenberg A., and Cherney B. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J. Pharm. Sci. 98 (2009) 1201-1205
4. Cataliotti A., Schirger J.A., Martin F.L., Chen H.H., Mckie P.M., Boerrigter G., Costello-Boerrigter L.C., Harty G., Heublein D.M., Sandberg S.M., James K.D., Miller M.A., Malkar N.B., Polowy K., and Burnett Jr. J.C. Oral human brain natriuretic peptide activates cyclic guanosine 3′,5′-monophosphate and decreases mean arterial pressure. Circulation 112 (2005) 836-840
5. Cheng W., and Lim L.-Y. Comparison of reversible and non reversible aqueoussoluble lipidized conjugates of salmon calcitonin. Mol. Pharm. 5 (2008) 610-621
6. Cheng W., Satyanarayanajois S., and Lim L.Y. Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm. Res. 24 (2007) 99-110
7. Claes P., Dunford M., A.K., and P.V. An on-line dynamic light scattering instrument for macromolecular charaterisation. In: Harding S.E., Sattelle D.B., and Bloomfield V.A. (Eds). Laser Light Scattering in Biochemistry (1992), Royal Society of Chemistry, Cambridge, England
8. Clement S., Dandona P., Still J.G., and Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53 (2004) 54-58
9. Clodfelter D.K., Nussbaum M.A., and Reilly J. Comparison of free solution capillary electrophoresis and size exclusion chromatography for quantitating non-covalent aggregation of an acylated peptide. J. Pharm. Biomed. Anal. 19 (1999) 763-775
10. Clodfelter D.K., Pekar A.H., Rebhun D.M., Destrampe K.A., Havel H.A., Myers S.R., and Brader M.L. Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide. Pharm. Res. 15 (1998) 254-262
11. Dicostanzo C.A., Moore M.C., Lautz M., Scott M., Farmer B., Everett C.A., Still J.G., Higgins A., and Cherrington A.D. Simulated first-phase insulin release using Humulin or insulin analog HIM2 is associated with prolonged improvement in postprandial glycemia. Am. J. Physiol. Endocrinol. Metab. 289 (2005) E46-52
12. Drin G., Cottin S., Blanc E., Rees A.R., and Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 278 (2003) 31192-31201
13. Ekrami H.M., Kennedy A.R., and Shen W.C. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett. 371 (1995) 283-286
14. Ekwuribe, N., Ramaswamy, M. Rajagopalan, J. S. (2001) Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same. In Office, U.S.P.A.T. (Ed.) United States Patent and Trademark Office. US, Nobex Corporation.
15. Gilbert H.F. Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol. 251 (1995) 8-28
16. Goldberg M., and Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 (2003) 289-295
17. Grillo A.O., Edwards K.L., Kashi R.S., Shipley K.M., Hu L., Besman M.J., and Middaugh C.R. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 40 (2001) 586-595
18. Hofland H.E., Bouwstra J.A., Verhoef J.C., Buckton G., Chowdry B.Z., Ponec M., and Junginger H.E. Safety aspects of non-ionic surfactant vesicles: a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J. Pharm. Pharmacol. 44 (1992) 287-294
19. Jemal M., and Hawthorne D.J. Quantitative determination of BMS-186716, a thiol compound, in rat plasma by high-performance liquid chromatography-positive ion electrospray mass spectrometry after hydrolysis of the methyl acrylate adduct by the native esterases. J. Chromatogr. B: Biomed. Sci. Appl. 698 (1997) 123-132
20. Kipnes M., Dandona P., Tripathy D., Still J.G., and Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care 26 (2003) 421-426
21. Larhed A.W., Artursson P., and Bjork E. The influence of intestinal mucus components on the diffusion of drugs. Pharm. Res. 15 (1998) 66-71
22. Lee S., Kim K., Kumar T.S., Lee J., Kim S.K., Lee D.Y., Lee Y.K., and Byun Y. Synthesis and biological properties of insulin-deoxycholic acid chemical conjugates. Bioconjug. Chem. 16 (2005) 615-620
23. Liederer B.M., Phan K.T., Ouyang H., and Borchardt R.T. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration. J. Pharm. Sci. 94 (2005) 2676-2687
24. Lindgren M.E., Hallbrink M.M., Elmquist A.M., and Langel U. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem. J. 377 (2004) 69-76
25. Miller M.A., Malkar N.B., Severynse-Stevens D., Yarbrough K.G., Bednarcik M.J., Dugdell R.E., Puskas M.E., Krishnan R., and James K.D. Amphiphilic conjugates of human brain natriuretic peptide designed for oral delivery: in vitro activity screening. Bioconjug. Chem. 17 (2006) 267-274
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
27. Ohyashiki T., Taka M., and Mohri T. Changes in the membrane surface charge density and/or membrane potential of the porcine intestinal brush-border membrane vesicles induced by treatment with neuraminidase. J. Biochem. 106 (1989) 584-588
28. Olsen H.B., and Kaarsholm N.C. Structural effects of protein lipidation as revealed by LysB29-myristoyl, des(B30) insulin. Biochemistry 39 (2000) 11893-11900
29. Pooga M., Kut C., Kihlmark M., Hallbrink M., Fernaeus S., Raid R., Land T., Hallberg E., Bartfai T., and Langel U. Cellular translocation of proteins by transportan. FASEB J. 15 (2001) 1451-1453
30. Price C. NOBEX Corporation: crossing barriers for better drug delivery. Drug Deliv. Technol. (2003) 3
31. Puri N.K., Crivelli E., Cardamone M., Fiddes R., Bertolini J., Ninham B., and Brandon M.R. Solubilization of growth hormone and other recombinant proteins from Escherichia coli inclusion bodies by using a cationic surfactant. Biochem. J. 285 Pt 3 (1992) 871-879
32. Ramasamy I. Recent advances in physiological calcium homeostasis. Clin. Chem. Lab. Med. 44 (2006) 237-273
33. Ryser H.J., and Hancock R. Histones and basic polyamino acids stimulate the uptake of albumin by tumor cells in culture. Science 150 (1965) 501-503
34. Scriba G.K. Phenytoin-lipid conjugates: chemical, plasma esterase-mediated, and pancreatic lipase-mediated hydrolysis in vitro. Pharm. Res. 10 (1993) 1181-1186
35. Seyferth S., and Lee G. Structural studies of EDTA-induced fibrillation of salmon calcitonin. Pharm. Res. 20 (2003) 73-80
36. Sharma A., and Jusko W.J. Characterization of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 24 (1996) 611-635
37. Siepmann J., and Gopferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv. Drug Deliv. Rev. 48 (2001) 229-247
38. Sigma-Adrich MSDS form of Thyrocalcitonin Salmon.
39. Sinko P.J., Smith C.L., Mcwhorter L.T., Stern W., Wagner E., and Gilligan J.P. Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats. J. Pharm. Sci. 84 (1995) 1374-1378
40. Vakil R., and S. Kwon G. Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles. Mol. Pharm. 5 (2008) 98-104
41. Wang J., Chow D., Heiati H., and Shen W.C. Reversible lipidization for the oral delivery of salmon calcitonin. J. Control. Release 88 (2003) 369-380
42. Wang J., Shen D., and Shen W.C. Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity. Pharm. Res. 16 (1999) 1674-1679
43. Wang J., and Shen W.C. Gastric retention and stability of lipidized Bowman-Birk protease inhibitor in mice. Int. J. Pharm. 204 (2000) 111-116
44. Wang J., Wu D., and Shen W.C. Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm. Res. 19 (2002) 609-614
45. Wendelaar Bonga S.E., and Pang P.K. Control of calcium regulating hormones in the vertebrates: parathyroid hormone, calcitonin, prolactin, and stanniocalcin. Int. Rev. Cytol. 128 (1991) 139-213
46. Yang J.Z., Chen W., and Borchardt R.T. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J. Pharmacol. Exp. Ther. 303 (2002) 840-848
47. Yoshida H., Lehr C.M., Kok W., Junginger H.E., Verhoef J.C., and Bouwstra J.A. Niosomes for oral delivery of peptide drugs. J. Control. Release 21 (1992) 145-153
48. Yuan L., Wang J., and Shen W.C. Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm. Res. 22 (2005) 220-227